Fig. 6
From: The role of CD180 in hematological malignancies and inflammatory disorders
CD180 signaling in CLL. CD180 can signal dichotomously via a pro-survival BTK/PI3K/AKT pathway or via a pro-apoptotic pathway mediated by p38MAPK, which is accompanied by a downregulation of AKT. Activation of the AKT axis, which is thought to also involve activation of PI3K, mediates an increase in anti-apoptotic Mcl-1 and BCL-XL activity; and is also coupled with a downregulation in p38MAPK. Pre-engagement of CD180 can inhibit AKT-mediated signaling via IgM (dashed line), which tends to be accompanied by an increase in the phosphorylation of p38MAPK and the number of apoptotic CLL cells. Co-ligation of both CD150 and CD180 together attenuates both of AKT and p38MAPK pathway signaling